Work at the Agency For Science Technology & Research Bioprocessing Technology Institute has led to the identification of mitogen-activated protein kinase kinase kinase 14 (MAP3K14; NIK) inhibitors reported to be useful for the treatment of pulmonary fibrosis.

Intra-Cellular Therapies Inc. has patented compounds acting as serotonin transporter (SERT), 5-HT2A, dopamine D1 and D2 receptor ligands reported to be useful for the treatment of neurological disorders.

Guangzhou Maxinovel Pharmaceuticals Co. Ltd. has described thienopyrimidine compounds acting as ALK, fibroblast growth factor receptor (FGFR) and high affinity nerve growth factor (TRK) inhibitors reported to be useful for the treatment of cancer, infections and psoriasis and inflammation.

Nammi Therapeutics Inc. has divulged prodrugs of Toll-like receptor (TLR) agonists and its self-assembled lipid nanoparticles reported to be useful for the treatment of cancer and immunological disorders.

Scinnohub Pharmaceutical Co. Ltd. has identified S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer. 

Shanghai Ringene Biopharma Co. Ltd. has synthesized CDK7/cyclin H inhibitors reported to be useful for the treatment of cancer, hemolytic anemia, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, sepsis, idiopathic thrombocytopenic purpura and ulcerative colitis, among others.

JS Innomed Holdings Ltd. has disclosed heterocyclic compounds acting as tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer, LEOPARD syndrome and Noonan syndrome.

Merck Sharp & Dohme Ltd. has described ceramide glucosyltransferase (glucosylceramide synthase; GLCT-1) inhibitors reported to be useful for the treatment of cancer, Lewy body dementia, diabetes, obesity, polycystic kidney disease, neurodegeneration, lysosomal storage disease and Parkinson’s disease, among others.

Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co Ltd. have identified heterocyclic derivatives acting as Ras-related C3 botulinum toxin substrate 1 (RAC1; TC25) inhibitors reported to be useful for the treatment of melanoma, Menkes disease, rheumatoid arthritis, atherosclerosis, type 1 diabetes, Huntington’s disease and Alzheimer’s disease.

Astellas Pharma Inc. has divulged proteolysis targeting chimera (PROTAC) compounds acting as GTPase KRAS (G12D mutant) degradation inducers reported to be useful for the treatment of pancreatic cancer.